Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, including statistics on global market size, regional shares, competitor analysis, market trends, and opportunities.
The radioligand therapy (RLT) market is experiencing significant growth, with the size projected to increase from $6.63 billion in 2025 to $7.32 billion in 2026, at a compound annual growth rate (CAGR) of 10.4%. This expansion is driven by factors such as the limited availability of radioligands, growing awareness of targeted therapy benefits, and increasing hospital adoption of nuclear medicine techniques. Early drug regulatory approvals have also played a crucial role in historic growth.
Looking ahead, the RLT market is expected to escalate further, reaching $10.72 billion by 2030 with a CAGR of 10%. This is attributed to the development of novel alpha and beta emitters, expansion of combined emission therapies, and integration with precision oncology. Additionally, rising clinical trials for neurological and cardiovascular applications and growing investment in home care and outpatient RLT services contribute to this forecast. Notable trends include the adoption of targeted therapy for oncology, integration with personalized medicine, and a focus on minimizing side effects while enhancing patient outcomes.
The increasing incidence of cancer is a primary catalyst for the RLT market. Radioligand therapy precisely targets tumors, sparing healthy tissue and delivering internal radiation for effective cell elimination. In October 2025, the UK's NHS reported 354,820 new cancer cases, highlighting this rising trend as a market driver.
Key companies are advancing facilities to enhance RLT production, quality, and safety. Novartis AG, for instance, automated its expansive RLT plant in Indiana, reflecting the industry's commitment to increased supply efficiency. This facility, the company's largest and most sophisticated, began operations after receiving FDA approval for commercial RLT production in early 2024.
In a major industry development, Eli Lilly and Company acquired POINT Biopharma Global Inc. for $1.4 billion in December 2023. This acquisition strengthens Eli Lilly's oncology portfolio with cutting-edge radioligand technologies for precise cancer treatments.
Leading companies in the market include Novartis AG, Lantheus Holdings Inc., Curium LLC, and others. While North America was the largest region in the RLT market in 2025, Asia-Pacific is anticipated to be the fastest-growing region moving forward. The geographical coverage of the RLT market report includes Asia-Pacific, North America, and Europe, along with various other regions and countries.
Reasons to Purchase:
Report Scope
Markets Covered:
Subsegments:
Countries and Regions: Includes Australia, Brazil, China, Europe, USA, Southeast Asia, amongst others.
Data Segmentation and Sourcing: The report employs country and regional historic data, market shares, and segmented market size information sourced using robust referencing methods.
Key Attributes
The companies featured in this Radioligand Therapy market report include:
For more information about this report visit https://www.researchandmarkets.com/r/ko3fxv
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment